FIELD: medicine, pharmacy.
SUBSTANCE: pharmaceutical composition possesses an anti-estrogenic effect. The composition comprises fulvestrant in ricinoleate vehicle, a pharmaceutically acceptable anhydrous ester solvent and pharmaceutically acceptable alcohol. The composition is adopted for intramuscular administration and maintains the therapeutically significant blood plasma fulvestrant concentration for at least 2 weeks. The composition for intramuscular injection provides satisfied releasing fulvestrant for prolonged time.
EFFECT: valuable medicinal and pharmaceutical properties of composition.
32 cl, 4 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| APPLICATION OF FULVESTRANT AT TREATING RESISTANT CANCER OF MAMMARY GLAND | 2001 |
|
RU2265438C2 |
| ABIRATERONE PRODRUGS | 2020 |
|
RU2822219C2 |
| FULVESTRANT COMPOSITIONS | 2018 |
|
RU2684330C1 |
| PHARMACEUTICAL COMPOSITIONS FOR PROLONGED RELEASE OF SEBACOYL-DINALBUPHINE ESTER | 2016 |
|
RU2718900C2 |
| METHOD AND PHARMACEUTICAL COMPOSITIONS FOR RELIABLE ACHIEVEMENT OF ACCEPTABLE LEVELS OF TESTOSTERONE IN SERUM | 2004 |
|
RU2354381C2 |
| DELAYED RELEASE BUPRENORPHINE PREPARATIONS | 2017 |
|
RU2747306C2 |
| PHARMACEUTICAL COMPOSITION OF ANALGETIC AGENT AND METHOD OF ITS PREPARING | 1996 |
|
RU2141845C1 |
| CONTROLLED DELIVERY SYSTEM | 2005 |
|
RU2429882C2 |
| COMPOSITIONS OF LONG-TERM ACTION BASED ON KETOPROFEN | 2014 |
|
RU2646829C1 |
| MEDICINAL AGENTS WITH CONTROLLED RELEASE BASED ON BLOCK-COPOLYMERS | 2006 |
|
RU2409348C2 |
